Colorado Blood Cancer Institute ( Site 0225) — Denver, Colorado

Colorado Blood Cancer Institute ( Site 0225) is a clinical research site located in Denver, Colorado, United States 80218.

Crixeo Health Trust Score: 58/100 (POOR). This profile has not yet been claimed by the site owner.

Colorado Blood Cancer Institute ( Site 0225) has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Lymphoma, B-Cell, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia.

Sponsors: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA).

Sponsor Feasibility Report

Trust Score: 58/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Colorado Blood Cancer Institute ( Site 0225)?

Colorado Blood Cancer Institute ( Site 0225) has a Crixeo Trust Score of 58/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Colorado Blood Cancer Institute ( Site 0225) conducted?

Colorado Blood Cancer Institute ( Site 0225) has 1 clinical trials on record, with 1 currently active. Their work covers Lymphoma, B-Cell, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia.

Is Colorado Blood Cancer Institute ( Site 0225) accredited by Crixeo Health?

Colorado Blood Cancer Institute ( Site 0225) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Colorado Blood Cancer Institute ( Site 0225)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.